Loading…
Bioventus Inc. is projected to rise to $17.42 by 2027, a +32% move from its current price of $13.17. BVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $12.79 | $13.18 | $13.57 | +0.05% |
| Aug 3 | $12.65 | $13.18 | $13.74 | +0.09% |
| Aug 4 | $12.53 | $13.19 | $13.88 | +0.14% |
| Aug 5 | $12.44 | $13.19 | $13.99 | +0.18% |
| Aug 6 | $12.36 | $13.20 | $14.10 | +0.23% |
| Aug 7 | $12.29 | $13.21 | $14.19 | +0.28% |
| Aug 8 | $12.23 | $13.21 | $14.28 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.23 | $13.21 | $14.28 | +0.32% |
| Week 2 | $11.88 | $13.26 | $14.79 | +0.65% |
| Week 3 | $11.62 | $13.30 | $15.21 | +0.97% |
| Week 4 | $11.42 | $13.34 | $15.58 | +1.30% |
| Week 5 | $11.25 | $13.38 | $15.92 | +1.63% |
| Week 6 | $11.10 | $13.43 | $16.24 | +1.95% |
| Week 7 | $10.97 | $13.47 | $16.54 | +2.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Its product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc. (BVS) current price is $13.21. It has a market cap of $894.95M and is ranked 2517.
The stock sits in a broader price trajectory that forecasts upside over the coming years, with a 2026 min of $7.21, a 2026 avg of $13.21, and a 2026 max of $19.13. By 2030, the avg rises to $24.77 with a max of $37.64 and a notable long-run upside through 2040 ($96.77 avg; $175.11 max) and 2050 ($185.74 avg; $372.45 max). The forecast shows bullish sentiment from 2027 onward, with increasingly large ROI potential through 2050 (e.g., 29.6% in 2027 up to 1306.1% in 2050).
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 33.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 23.0% above — clearing it would confirm fresh momentum.
Key BVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.03 | Buy | $12.93 | Buy |
| MA 10 | $12.35 | Buy | $12.57 | Buy |
| MA 20 | $12.15 | Buy | $11.98 | Buy |
| MA 50 | $10.32 | Buy | $10.94 | Buy |
| MA 100 | $9.98 | Buy | $10.13 | Buy |
| MA 200 | $8.83 | Buy | $9.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.32 | Neutral |
| Stoch RSI (14) | 90.04 | Sell |
| CCI (20) | 144.02 | Buy |
| Williams %R (14) | -2.31 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 10.03 | Buy |
| Bollinger %B (20,2) | 0.94 | Neutral |
| Stochastic %K (14) | 97.69 | Sell |
| TRIX (15) | 0.96 | Buy |
| Awesome (5,34) | 2.06 | Buy |
| Ultimate (7,14,28) | 77.94 | Sell |
| Momentum (10) | 1.11 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 13.56 | Sell |
| ADX (14) | 28.47 | Buy |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bullish with RSI14 at 60.0, and moving averages above the recent price.
SMA50 is $10.09 and SMA200 is $8.68, with near-term support at $8.51 and resistance at $12.45. The 30-day range spans from a low of $10.59 to a high of $16.48, signaling upside potential within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.21 | $13.17 | $18.85 | 0% | Neutral | |
| $13.80 | $17.42 | $23.31 | +32% | Bullish | |
| $16.24 | $21.15 | $29.45 | +61% | Bullish | |
| $16.95 | $22.63 | $32.52 | +72% | Bullish | |
| $19.49 | $26.62 | $39.25 | +102% | Bullish | |
| $24.67 | $34.38 | $51.85 | +161% | Bullish | |
| $28.97 | $41.14 | $63.32 | +212% | Bullish | |
| $34.19 | $49.43 | $77.48 | +275% | Bullish | |
| $38.21 | $56.18 | $89.56 | +327% | Bullish | |
| $39.82 | $59.52 | $96.37 | +352% | Bullish | |
| $67.38 | $108.43 | $187.39 | +723% | Bullish | |
| $118.47 | $216.76 | $411.71 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.21 | $13.17 | $16.21 | +0.00% |
| September 2026 | $11.27 | $13.37 | $16.32 | +1.49% |
| October 2026 | $11.50 | $13.74 | $16.96 | +2.77% |
| November 2026 | $12.14 | $14.59 | $18.19 | +6.24% |
| December 2026 | $12.41 | $15.00 | $18.85 | +2.78% |
Click any year to see its month-by-month BVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BVS could reach as high as $18.85, with a base case around $13.17 and support toward $7.21 — roughly 0% from $13.17. Price action looks broadly range-bound.
Expect BVS to range from $13.80 to $23.31 through 2027. The $17.42 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BVS price prediction for 2028 points to an average of $21.15 (low $16.24, high $29.45) — a potential gain of +61% on today's $13.17. Momentum favours further upside here.
In 2029, BVS is projected to trade between $16.95 and $32.52, averaging $22.63 — a potential gain of +72% from today's $13.17. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Bioventus Inc.'s 2030 outlook centres on $26.62, within a $19.49 to $39.25 range. That is up +18% on the projected 2029 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2031, BVS could reach as high as $51.85, with a base case around $34.38 and support toward $24.67 — roughly +161% from $13.17. Buyers look set to stay in control over this stretch.
Expect BVS to range from $28.97 to $63.32 through 2032. The $41.14 average target implies a +212% move from current prices. That is up +20% on the projected 2031 average. Momentum favours further upside here.
The BVS price prediction for 2033 points to an average of $49.43 (low $34.19, high $77.48) — a potential gain of +275% on today's $13.17. Buyers look set to stay in control over this stretch.
In 2034, BVS is projected to trade between $38.21 and $89.56, averaging $56.18 — a potential gain of +327% from today's $13.17. That is up +14% on the projected 2033 average. Momentum favours further upside here.
Bioventus Inc.'s 2035 outlook centres on $59.52, within a $39.82 to $96.37 range. That is up +6% on the projected 2034 average. That marks a +352% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BVS could reach as high as $187.39, with a base case around $108.43 and support toward $67.38 — roughly +723% from $13.17. Momentum favours further upside here.
Expect BVS to range from $118.47 to $411.71 through 2050. The $216.76 average target implies a +15.5x move from current prices. That is up +100% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BVS today (≈ 75.930144 BVS) could be worth
$16,458.83
+$15,458.83 (+1546%) by 2050 · US Dollar
Based on the average projected BVS price of $216.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BVSwould be worth at today's price.
$1,000 invested in BVS on Jul 31, 2025 (≈ 153.374234 BVS) would be worth
$2,019.94
+$1,019.94 (+102.0%) today · 2.02× · US Dollar
Based on a BVS entry price of $6.52 vs. today's $13.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.8 | $1,116.1 | +11.6% |
| 1 month ago | $9.85 | $1,337.06 | +33.7% |
| 3 months ago | $10.11 | $1,302.67 | +30.3% |
| 6 months ago | $8.21 | $1,604.14 | +60.4% |
| 1 year ago | $6.52 | $2,019.94 | +102.0% |
| All time (5.0y) ago | $14.8 | $889.86 | -11.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BVS forecast.
Our base-case forecast reaches $26.00 around 2030.
Implied market cap at $26.00: $1.76B
The multi-year forecast shows a clear path of upside beyond 2026, with steady gains in average prices and several years delivering strong returns.
In 2027 the average price is $17.12 with a 29.6% ROI, followed by 2028 at an average of $20.55 (55.5% ROI) and 2029 at $21.27 (61% ROI). By 2030 the average is $24.77 (87.5% ROI). The forecast continues to rise meaningfully into later years, with 2031 at $32.05 (142.6% ROI) and 2032 at $37.91 (187% ROI), and 2033 at $45.89 (247.4% ROI).
The 2040 forecast shows $96.77 average (632.5% ROI) and a max of $175.11, while 2050 projects an average of $185.74 with a max of $372.45 and a 1306.1% ROI. These figures imply bullish sentiment across most years, but they are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $24.77, min $17.65, max $37.64; ROI 87.5%; sentiment BULLISH.
Forecasts show bullish sentiment in 2027-2050 with rising average prices (e.g., 2027 avg $17.12, 2030 avg $24.77, 2040 avg $96.77, 2050 avg $185.74); these are estimates and not guarantees.
Yes. The 2040 max is $175.11 and the 2050 max is $372.45, so it could reach above $100 by 2040 in the upside scenario.
Current price is $13.21 and market cap is $894.95M.
30-day range low $10.59 and high $16.48.
Bioventus Inc. Community Discussion
0Share your Bioventus Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.